Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Randomised, double-blind trial of carboplatin and...
Journal article

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

Abstract

INTRODUCTION: This randomised double-blind placebo-controlled study evaluated the addition of cediranib, an inhibitor of vascular endothelial growth factor receptors 1-3, to standard carboplatin/paclitaxel chemotherapy in advanced non-small cell lung cancer. METHODS: Eligible patients received paclitaxel (200mg/m(2)) and carboplatin (area under the concentration time curve 6) intravenously every 3 weeks. Daily oral cediranib/placebo 20mg was …

Authors

Laurie SA; Solomon BJ; Seymour L; Ellis PM; Goss GD; Shepherd FA; Boyer MJ; Arnold AM; Clingan P; Laberge F

Journal

European Journal of Cancer, Vol. 50, No. 4, pp. 706–712

Publisher

Elsevier

Publication Date

3 2014

DOI

10.1016/j.ejca.2013.11.032

ISSN

0959-8049